{"id":175633,"name":"ASSOCIATION OF ACCESSIBLE MEDICINES","slug":"association-of-accessible-medicines","state":"DC","description":"Trade Association","totalSpending":1780000,"filings":31,"yearlySpending":[{"year":2018,"income":300000},{"year":2019,"income":120000},{"year":2020,"income":220000},{"year":2021,"income":220000},{"year":2022,"income":180000},{"year":2023,"income":200000},{"year":2024,"income":300000},{"year":2025,"income":240000}],"firms":["MEHLMAN CONSULTING, INC."],"lobbyists":["BRUCE MEHLMAN","DAVID CASTAGNETTI","DEAN ROSEN","DAVID THOMAS","ELISE FINLEY PICKERING","CHARLES WOOTERS","SOHINI GUPTA","SAGE EASTMAN","LAUREN ARONSON","MICHAEL ROBINSON","MICHAEL COLLINS","CONSTANTINE HINGSON","STEVE HARO","HELEN TOLAR","NICHOLE DISTEFANO","MCKENZIE BRICE","PAUL THORNELL","STEPHEN COTE","ALEXANDER PERKINS","VICTORIA FLOOD","ROSEMARY GUTIERREZ","ZACHARY MALLOVE","CAITLIN VAN SANT","LISA GOLDMAN","ALYENE MLINAR","ERICA CHABOT","ANNIE WOLF","NAVEEN PARMAR","ANNIE MLINAR (NAME ERROR)","JON ADAME","JOSEPH BROWN","EARL FLOOD"],"issues":["CPT","PHA","MMM","BUD","TRD","DIS",null,"HCR"],"sampleDescriptions":["Issues related to the use of sovereign immunity for patent protection.","S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).\nH.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).\nS. 1348 - Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 (SPIKE Act).\nMedicare Part D biosimilars; Medicaid generic rebate penalty.\nH.R. 1892 - Bipartisan Budget Act of 2018, Omnibus.","Medicare Part D biosimilars; Medicaid generic rebate penalty.","Generic prescription drug issues.\nH.R. 1892 - Bipartisan Budget Act of 2018, Omnibus.","Monitoring trade/tariff issues.","S. 974 - Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act).\nH.R. 2051 - Fair Access for Safe and Timely Generics Act of 2017 (FAST Generics Act of 2017).\nS. 1348 - Stopping the Pharmaceutical Industry from Keeping Drugs Expensive Act of 2017 (SPIKE Act).\nMedicare Part D biosimilars; Medicaid generic rebate penalty.","Generic prescription drug issues.","Issues related to the sovereign immunity for patent protection.  Issues related to patents and inter partes review.\nS. 440 - PACED Act\nH.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019","Medicaid and Medicare drug pricing.\nPrescription drug pricing.\nS. 340 - CREATES Act of 2019.\nH.R. 965 - CREATES Act of 2019.\nH.R. 985 -  FAST Generics Act of 2019.\nS.1895 - Lower Health Care Costs Act.\nS. 1416 - Affordable Prescriptions for Patients Act of 2019\nS. 440 - PACED Act\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R. 938 - BLOCKING Act of 2019\nH.R. 1520 - Purple Book Continuity Act of 2019\nH.R. 1503 - Orange Book Transparency Act of 2019\nH.R. 3 - Lower Drug Costs Now Act of 2019\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019","Medicaid generic rebate policy; medicare low-income subsidy (LIS) rebate.","Fiscal Year 2020 Appropriations.","USMCA","Medicaid and Medicare drug pricing.\nPrescription drug pricing.\nS. 340 - CREATES Act of 2019.\nH.R. 965 - CREATES Act of 2019.\nH.R. 985 -  FAST Generics Act of 2019.\nS.1895 - Lower Health Care Costs Act.\nS. 1416 - Affordable Prescriptions for Patients Act of 2019\nS. 440 - PACED Act\nH.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R. 2375 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R. 938 - BLOCKING Act of 2019\nH.R. 1520 - Purple Book Continuity Act of 2019\nH.R. 1503 - Orange Book Transparency Act of 2019\nH.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019\nH.R. 1865 - Further Consolidated Appropriations Act, 2020","Medicaid generic rebate policy; medicare low-income subsidy (LIS) rebate.\nH.R. 1865 - Further Consolidated Appropriations Act, 2020","Fiscal Year 2020 Appropriations.\nH.R. 1865 - Further Consolidated Appropriations Act, 2020","Medicaid generic rebate policy; medicare low-income subsidy (LIS) rebate.\nS. 2543 - Prescription Drug Pricing Reduction Act","Fiscal Year 2021 Appropriations.","Issues related to the sovereign immunity for patent protection.  Issues related to patents and inter partes review.","Medicaid and Medicare drug pricing.\nPrescription drug pricing.\nH.R. 965 - CREATES Act of 2019.\nH.R. 985 -  FAST Generics Act of 2019.\nS.1895 - Lower Health Care Costs Act.\nS. 440 - PACED Act\nH.R. 938 - BLOCKING Act of 2019\nH.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act\nS. 2543 - Prescription Drug Pricing Reduction Act of 2019","HR 266 - Paycheck Protection Program and Health Care Enhancement Act\nHR 6800 - HEROES Act"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}